Policy Intel & Events

Policy Intel & Events

The Latest from Roberti Global

Roberti Global insights on policy trends, political analysis, firm updates, and front-line perspectives from Washington.

AllEventsFirm UpdateMediaPolicy Intel
Media
Eisai-Developed Treatment for Alzheimer’s Disease Approved by FDA

Eisai Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for once weekly lecanemab-irmb subcutaneous injection (U.S. brand name: LEQEMBI® IQLIKTM) for maintenance dosing. LEQEMBI IQLIK is a subcutaneous autoinjector (SC-AI) developed by Eisai, containing 360 mg/1.8 mL (200 mg/mL)

Firm Update
American Pharmacies Annual Fly-In Event

Roberti Global was proud to host American Pharmacies for its annual DC fly-in this September, facilitating nearly 50 meetings with congressional offices over three days in support of pharmacy benefit manager (PBM) reform. The whirlwind tour was topped off with a delightful dinner among colleagues that featured an appearance by

Events
Eisai U.S. Baltimore Manufacturing Site Ribbon-Cutting Ceremony

Roberti Global was honored to join community leaders and partners in celebrating Eisai for receiving final regulatory approval for its new site in Baltimore, MD – the only site in the world that manufactures a specialized implant relied upon by thousands each year in the treatment of a rare form

Firm Update
American Pharmacies Annual Fly-In Event
Firm Update
American Pharmacies Annual Fly-In Event
Events
Eisai U.S. Baltimore Manufacturing Site Ribbon-Cutting Ceremony
Events
Eisai U.S. Baltimore Manufacturing Site Ribbon-Cutting Ceremony
Media
Eisai-Developed Treatment for Alzheimer’s Disease Approved by FDA
Media
Eisai-Developed Treatment for Alzheimer’s Disease Approved by FDA